Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 2:22 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 310 matching trials from the live ClinicalTrials.gov search.
Conditions
Meningitis, Meningococcal Infection
Interventions
MenACWY-CRM197, DTaP (Diptheria, Tetanus, Pertussis) Vaccine, Hib (Haemophilus influenza b) Vaccine, IPV (Inactivated Polio Vaccine) Vaccine, Pneumococcal conjugate Vaccine, MMR (Measles, Mumps, and Rubella) Vaccine, Varicella Vaccine, Hepatitis A Virus
Biological
Lead sponsor
Novartis
Industry
Eligibility
55 Days to 89 Days
Enrollment
7,744 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
130
States / cities
Birmingham, Alabama • Dothan, Alabama • Tuscon, Arizona + 107 more
Conditions
Influenza
Interventions
Trivalent influenza vaccine GSK 138842A, Fluarix
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 49 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
2
States / cities
Miami, Florida • Lenexa, Kansas
Conditions
Influenza
Interventions
CAIV-T 10^7, CAIVT 10^5, Placebo, TIV
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
6 Months to 36 Months
Enrollment
173 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001
U.S. locations
2
States / cities
New Port Richey, Florida • Pittsburgh, Pennsylvania
Conditions
Influenza, Human Prevention, Respiratory Syncytial Viruses Prevention
Interventions
Ad26.RSV.preF-based vaccine, Quadrivalent High-dose Influenza Vaccine, Placebo
Biological
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
65 Years and older
Enrollment
777 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
19
States / cities
Long Beach, California • Hollywood, Florida • Port Orange, Florida + 14 more
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study of mRNA-1010 Seasonal Influenza Vaccine in Adults

NCT05827978
Conditions
Seasonal Influenza
Interventions
mRNA-1010, Licensed Quadrivalent Inactivated Seasonal Influenza Vaccine
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years and older
Enrollment
8,411 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
103
States / cities
Anniston, Alabama • Athens, Alabama • Cullman, Alabama + 85 more
Conditions
Avian Influenza
Interventions
AS03, MF59, Monovalent Influenza A/H5N8 vaccine
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
19 Years to 64 Years
Enrollment
388 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
7
States / cities
Atlanta, Georgia • Baltimore, Maryland • St Louis, Missouri + 4 more
Conditions
Influenza
Interventions
Influenza Vaccination
Biological
Lead sponsor
Protein Sciences Corporation
Industry
Eligibility
65 Years and older
Enrollment
870 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
7
States / cities
Baltimore, Maryland • Rochester, Minnesota • Shrewsbury, New Jersey + 3 more
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Flublok or Fluzone With Advax-CpG55.2 or AF03

NCT03945825
Conditions
Influenza, Influenza Immunisation
Interventions
AF03, Delta Inulin-CpG55.2, Influenza Virus Quadrivalent Inactivated Vaccine, Quadrivalent Recombinant Seasonal Influenza Vaccine
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
241 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
8
States / cities
Atlanta, Georgia • Iowa City, Iowa • Baltimore, Maryland + 5 more
Completed Not applicable Interventional Results available

Open-Label Influenza Vaccine Evaluation

NCT02872311
Conditions
Immune Response
Interventions
High Dose Influenza vaccine, Adjuvanted Influenza vaccine, Standard Dose Influenza vaccine, Recombinant Influenza vaccine
Biological
Lead sponsor
Marshfield Clinic Research Foundation
Other
Eligibility
65 Years to 74 Years
Enrollment
179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Marshfield, Wisconsin
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed, Ibrutinib, Laboratory Biomarker Analysis, Pharmacological Study, Pneumococcal 13-valent Conjugate Vaccine, Quality-of-Life Assessment, Trivalent Influenza Vaccine
Biological · Drug · Other
Lead sponsor
Jennifer Woyach
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Higher Dose Intradermal H5 Vaccine

NCT00439335
Conditions
Influenza
Interventions
Inactivated Influenza A Vaccine A/H5N1, Placebo (IM), Placebo (ID)
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
227 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Houston, Texas
Conditions
Influenza, Human
Interventions
FLU Q-PAN H5N8 375_B, FLU Q-PAN H5N8 375_A, FLU Q-PAN H5N8 750_B, FLU Q-PAN H5N8 750_A
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
518 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
20
States / cities
Anniston, Alabama • Mobile, Alabama • Tempe, Arizona + 17 more
Conditions
Seasonal Influenza
Interventions
mRNA-1011.1, mRNA-1011.2, mRNA-1012.1, mRNA-1010, mRNA-1010.2, mRNA-1010.3
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
50 Years to 75 Years
Enrollment
698 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
22
States / cities
Lakewood, California • Long Beach, California • Fort Collins, Colorado + 19 more
Recruiting No phase listed Observational Accepts healthy volunteers

Understanding Immunity to the Flu Vaccine in COVID-19 Patients

NCT04579588
Conditions
Corona Virus Infection, Flu Vaccine, Immunity
Interventions
Flu shot
Biological
Lead sponsor
Stanford University
Other
Eligibility
9 Years to 64 Years
Enrollment
230 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2028
U.S. locations
1
States / cities
Palo Alto, California
Conditions
Influenza
Interventions
Fluarix, Fluzone
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Months to 35 Months
Enrollment
3,317 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
62
States / cities
Birmingham, Alabama • Dothan, Alabama • Benton, Arkansas + 58 more
Conditions
Influenza A Subtype H7N7 Infection
Interventions
Monovalent Influenza Subvirion Vaccine, H7N7
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Rochester, New York
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Entolimod on Immunosenescence in Healthy Geriatric Subjects Receiving Influenza Vaccination

NCT04176133
Conditions
Healthy
Interventions
Entolimod, Placebo, Influenza vaccine
Drug
Lead sponsor
Robert J. Pignolo
Other
Eligibility
65 Years and older
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of Flublok Quadrivalent vs IIV4 in Adults 18-49 Years of Age

NCT02290509
Conditions
Influenza
Interventions
Flublok Quadrivalent, Inactivated Influenza Vaccine (IIV4)
Biological
Lead sponsor
Protein Sciences Corporation
Industry
Eligibility
18 Years to 49 Years
Enrollment
1,350 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
10
States / cities
Sacramento, California • Coral Gables, Florida • Savannah, Georgia + 7 more
Conditions
Influenza, Vaccination, Health Promotion, Health Behavior, Risk Reduction
Interventions
Reminder, Risk reduction, Medical records-based recommendation, Algorithm-based recommendation
Behavioral
Lead sponsor
National Bureau of Economic Research, Inc.
Other
Eligibility
18 Years and older
Enrollment
45,061 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Danville, Pennsylvania
Conditions
Influenza
Interventions
QIV-HD, Licensed TIV-HD1, Investigational TIV-HD2
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
65 Years and older
Enrollment
2,670 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
36
States / cities
Anaheim, California • Redding, California • San Diego, California + 29 more
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

A Study of AV0328 Administered to Healthy Adult Volunteers

NCT02853617
Conditions
PNAG-expressing Pathogenic Microbes Vaccine
Interventions
AV0328 - Cohort 1, AV0328 - Cohort 2, AV0328 - Cohort 3, AV0328 - Cohort 4
Biological
Lead sponsor
Alopexx Vaccine, LLC
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Neptune City, New Jersey
Completed Not applicable Interventional Accepts healthy volunteers

Influenza Reminder Text-Messaging

NCT06587984
Conditions
Influenza
Interventions
Text message reminder
Behavioral
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
6 Months to 18 Years
Enrollment
228,361 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Study of mRNA-based Influenza and SARS-CoV-2 (COVID-19) Multi-component Vaccines in Healthy Adults

NCT05827926
Conditions
SARS-CoV-2, Influenza
Interventions
Influenza Vaccine 1, mRNA-1083.1, mRNA-1083.2, mRNA-1083.3, Investigational Influenza Vaccine 1, Investigational COVID-19 Vaccine 1, COVID-19 Vaccine 1, Investigational Influenza Vaccine 2, Influenza Vaccine 2, mRNA-1083, Investigational COVID-19 Vaccine 2, COVID-19 Vaccine 2
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years to 79 Years
Enrollment
1,758 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
69
States / cities
Chandler, Arizona • Colton, California • Huntington Beach, California + 59 more
Conditions
Influenza A Virus, H7N9 Subtype
Interventions
H7N9 pLAIV, H7N9 pIIV, AS03 adjuvant
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
20 Years to 49 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2016
U.S. locations
1
States / cities
Rochester, New York